Hair Transplant Fundamentals

Hair Transplant Fundamentals | AlviArmani Knowledge Hub Hair Transplant Fundamentals A modern hair restoration approach combines science, design, and surgical precision. In this guide, we explain how hair transplantation works at AlviArmani—from planning a hair transplant procedure to achieving a natural appearance—with an emphasis on donor preservation, density, and artistic design. follicular unit extraction (FUE)…

Read More

Hair Loss Basics

Hair Loss Basics | AlviArmani Knowledge Hub Hair Loss Basics Hair loss can be gradual or sudden, temporary or permanent—and it’s more common than you think. From hormonal shifts and genetics to stress and nutritional imbalances, there are many reasons people experience thinning or balding. At AlviArmani, we believe understanding the root cause is the…

Read More

AlviArmani Patient Journey Hub

AlviArmani Patient Journey | Follicle, Healing & Care AlviArmani Patient Journey Hub Discover the full AlviArmani journey—from follicle to full growth, healing timelines, testimonials, and expert post‑op guidance from Dr. Barton. Table of Contents Chapter 1: The Life of a Follicle Chapter 2: Day of Procedure – What to Expect Chapter 3: The Night After…

Read More

FUE Hair Transplant Statistics 2024: AlviArmani Case Analysis

AlviArmani US Retrospective Analysis of 2024 Procedure Types

FUE Hair Transplant Statistics 2024 — AlviArmani U.S. Case Analysis Precision and artistry in motion — data that defined a pivotal year. See how 2025 built on these results → View 2025 Case Insights “2024 was the year AlviArmani redefined scale — proving that precision and density could grow together. Every procedure reflected our commitment…

Read More

Is PP405 the Answer to Hair Loss?

Is PP405 The Answer To Hair Loss?

Updated September 2025 PP405 is a topical that targets follicle metabolism (MPC inhibition → glycolysis → regeneration), meeting its primary secondary pharmacokinetic endpoint of concentration. As of Sept 2025, Pelage Pharmaceuticals has announced positive results from the Phase 2a trial of PP405: the treatment met its primary safety endpoints and showed measurable efficacy, with ~31%…

Read More